Use of co-processed excipients in continuous manufacture of solid dosage forms
By introducing co-processed excipients, the pharmaceutical composition is simplified and composed of a small amount of excipients is solved, and the number of excipients in continuous pharmaceutical manufacturing is limited, manufacturing efficiency and economic benefits are improved, and the fluidity and bulk density of the tablet are ensured.
Patent Information
- Application Number
- CN202380057675.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-31
- Filing Date
- 2023-08-10
- Publication Date
- 2025-03-18
AI Technical Summary
In continuous pharmaceutical manufacturing, the manufacturing of solid pharmaceutical dosage forms is limited by the number of feeders on the equipment, usually only APIs and three to five excipients are used, and the use of premixes is economically inefficient, and it is necessary to simplify the pharmaceutical composition to consist of as few excipients as possible.
Co-processed excipients are introduced, and a combination of multiple single excipient functions is obtained by physical co-processing, simplifying the pharmaceutical composition to consist of 1 to 4 co-processed excipients.
It is achieved to simplify the pharmaceutical composition in continuous manufacturing, reduce the quantity of excipients, improve the manufacturing efficiency and economic benefits, and ensure the fluidity and bulk density of the tablets, ensuring the reliability of the tablet pressing process.